INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer's DiseaseGlobeNewsWire • 07/11/23
INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial BiologyGlobeNewsWire • 07/10/23
INmune Bio's Alzheimer's treatment merits a high-upside price target, analysts sayProactive Investors • 06/02/23
INmune Bio Inc.'s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene TherapyGlobeNewsWire • 05/24/23
INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate CancerGlobeNewsWire • 05/08/23
INmune Bio Inc. Announces First Quarter 2023 Results and Provides Business UpdateGlobeNewsWire • 05/03/23
INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3GlobeNewsWire • 04/24/23
XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer's DiseaseGlobeNewsWire • 04/19/23
INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03GlobeNewsWire • 04/11/23
INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune™ to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate CancerGlobeNewsWire • 04/03/23
INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2GlobeNewsWire • 02/21/23
INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United KingdomGlobeNewsWire • 02/08/23
INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular DystrophyGlobeNewsWire • 01/25/23
INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer's DiseaseGlobeNewsWire • 12/22/22
Wall Street Analysts Predict a 99% Upside in INmune Bio, Inc. (INMB): Here's What You Should KnowZacks Investment Research • 12/21/22
INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune™GlobeNewsWire • 12/08/22
INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast CancerGlobeNewsWire • 12/06/22
INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer's Disease TreatmentsGlobeNewsWire • 11/29/22